Literature DB >> 9732941

Enhanced phenotypic expression of alpha-1-antitrypsin deficiency in an MZ heterozygote with chronic hepatitis C.

B F Banner1, N Karamitsios, L Smith, H L Bonkovsky.   

Abstract

A middle-aged white man of Scotch-Irish ancestry, being treated for chronic hepatitis C, was found to be heterozygous for alpha1-antitrypsin deficiency (PiMZ phenotype) after diagnostic PAS-positive, diastase-resistant globules were detected in a liver biopsy. The globules had not been present in a biopsy obtained 4 yr previously. He was also found to be heterozygous for the cys282tyr mutation of the HFE gene, which is the chief cause of HLA-linked hereditary hemochromatosis (HHC). His liver disease progressed over 4 yr from mild hepatitis to moderate hepatitis with cirrhosis despite therapy with interferon-alpha, and phlebotomy plus interferon. These conditions appeared to have synergistic effects, with the chronic viral hepatitis unmasking the alpha1AT deficiency, and the alpha1AT deficiency (and possibly the heterozygosity for HHC), exacerbating the course of the hepatitis C.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9732941     DOI: 10.1111/j.1572-0241.1998.00478.x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  3 in total

Review 1.  Role of HFE gene mutations in liver diseases other than hereditary hemochromatosis.

Authors:  H L Bonkovsky; J V Obando
Journal:  Curr Gastroenterol Rep       Date:  1999 Feb-Mar

Review 2.  Alpha-1-antitrypsin deficiency: diagnosis, pathophysiology, and management.

Authors:  Jeffrey H Teckman; Douglas Lindblad
Journal:  Curr Gastroenterol Rep       Date:  2006-02

Review 3.  Alpha-1 antitrypsin deficiency: a conformational disease associated with lung and liver manifestations.

Authors:  C M Greene; S D W Miller; T Carroll; C McLean; M O'Mahony; M W Lawless; S J O'Neill; C C Taggart; N G McElvaney
Journal:  J Inherit Metab Dis       Date:  2008-01-16       Impact factor: 4.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.